329 related articles for article (PubMed ID: 22353219)
1. Developments in selective small molecule ATP-targeting the serine/threonine kinase Akt/PKB.
Wang P; Zhang L; Hao Q; Zhao G
Mini Rev Med Chem; 2011 Nov; 11(13):1093-107. PubMed ID: 22353219
[TBL] [Abstract][Full Text] [Related]
2. The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors.
Lindsley CW; Barnett SF; Layton ME; Bilodeau MT
Curr Cancer Drug Targets; 2008 Feb; 8(1):7-18. PubMed ID: 18288939
[TBL] [Abstract][Full Text] [Related]
3. Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors.
Lindsley CW; Barnett SF; Yaroschak M; Bilodeau MT; Layton ME
Curr Top Med Chem; 2007; 7(14):1349-63. PubMed ID: 17692025
[TBL] [Abstract][Full Text] [Related]
4. Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.
Liu Y; Wan WZ; Li Y; Zhou GL; Liu XG
Oncotarget; 2017 Jan; 8(4):7181-7200. PubMed ID: 27769061
[TBL] [Abstract][Full Text] [Related]
5. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update.
Lindsley CW
Curr Top Med Chem; 2010; 10(4):458-77. PubMed ID: 20180757
[TBL] [Abstract][Full Text] [Related]
6. Development for anticancer therapy: small-molecule inhibitors targeting protein kinase B.
Chen SF; Chen JZ
Mini Rev Med Chem; 2013 Jul; 13(9):1272-94. PubMed ID: 22512570
[TBL] [Abstract][Full Text] [Related]
7. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation.
Barnett SF; Bilodeau MT; Lindsley CW
Curr Top Med Chem; 2005; 5(2):109-25. PubMed ID: 15853641
[TBL] [Abstract][Full Text] [Related]
8. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.
Wu P; Hu YZ
Curr Med Chem; 2010; 17(35):4326-41. PubMed ID: 20939811
[TBL] [Abstract][Full Text] [Related]
9. Recent developments of small molecule PI3K/mTOR dual inhibitors.
Liu YN; Wan RZ; Liu ZP
Mini Rev Med Chem; 2013 Dec; 13(14):2047-59. PubMed ID: 24195664
[TBL] [Abstract][Full Text] [Related]
10. Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.
Mortensen DS; Perrin-Ninkovic SM; Harris R; Lee BG; Shevlin G; Hickman M; Khambatta G; Bisonette RR; Fultz KE; Sankar S
Bioorg Med Chem Lett; 2011 Nov; 21(22):6793-9. PubMed ID: 21978683
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.
Maira SM; Furet P; Stauffer F
Future Med Chem; 2009 Apr; 1(1):137-55. PubMed ID: 21426073
[TBL] [Abstract][Full Text] [Related]
12. Akt Pathway Inhibitors.
Uko NE; Güner OF; Matesic DF; Bowen JP
Curr Top Med Chem; 2020; 20(10):883-900. PubMed ID: 32091335
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy.
Chen YL; Law PY; Loh HH
Curr Med Chem Anticancer Agents; 2005 Nov; 5(6):575-89. PubMed ID: 16305480
[TBL] [Abstract][Full Text] [Related]
14. Discovery of inter-domain stabilizers-a novel assay system for allosteric akt inhibitors.
Fang Z; Simard JR; Plenker D; Nguyen HD; Phan T; Wolle P; Baumeister S; Rauh D
ACS Chem Biol; 2015 Jan; 10(1):279-88. PubMed ID: 24959717
[TBL] [Abstract][Full Text] [Related]
15. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
16. The PI3K/Akt/PTEN/mTOR pathway: a fruitful target for inducing cell death in rheumatoid arthritis?
Malemud CJ
Future Med Chem; 2015; 7(9):1137-47. PubMed ID: 26132523
[TBL] [Abstract][Full Text] [Related]
17. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors.
Blake JF; Xu R; Bencsik JR; Xiao D; Kallan NC; Schlachter S; Mitchell IS; Spencer KL; Banka AL; Wallace EM; Gloor SL; Martinson M; Woessner RD; Vigers GP; Brandhuber BJ; Liang J; Safina BS; Li J; Zhang B; Chabot C; Do S; Lee L; Oeh J; Sampath D; Lee BB; Lin K; Liederer BM; Skelton NJ
J Med Chem; 2012 Sep; 55(18):8110-27. PubMed ID: 22934575
[TBL] [Abstract][Full Text] [Related]
18. ATP-competitive inhibitors of mTOR: an update.
Schenone S; Brullo C; Musumeci F; Radi M; Botta M
Curr Med Chem; 2011; 18(20):2995-3014. PubMed ID: 21651476
[TBL] [Abstract][Full Text] [Related]
19. Targeted small-molecule inhibitors of protein kinase B as anticancer agents.
Collins I
Anticancer Agents Med Chem; 2009 Jan; 9(1):32-50. PubMed ID: 19149480
[TBL] [Abstract][Full Text] [Related]
20. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]